Jupiter Life Line Hospitals (JLHL) Q1 26/27 earnings summary

Executive summary

• Dombivli Hospital completed its first full quarter, contributing an EBITDA loss of ₹9.5 crore, with occupancy and patient footfall rising as expected during ramp-up and launch costs.

• Established hospitals maintained healthy occupancy, providing operational and financial stability.

• Consolidated revenue from operations for Q1 FY27 was ₹4,109.83 million, up from ₹3,529.53 million in Q1 FY26.

• Net profit attributable to owners for Q1 FY27 was ₹374.86 million, compared to ₹438.86 million in Q1 FY26.

• The group completed the acquisition of Sulcus Private Limited to set up a pharmaceutical manufacturing facility, aiming to reduce costs and improve margins.

Financial highlights

• Q1 FY27 revenue from operations rose 16.2% year-over-year to ₹392.6 crore; total income was ₹411 crore.

• EBITDA for Q1 FY27 was ₹79.3 crore (19.3% margin), up 1.1% year-over-year, but margin declined from 22.2% due to ramp-up losses and higher marketing costs.

• PAT for Q1 FY27 was ₹37.5 crore, down 14.7% year-over-year; PAT margin fell to 9.1%.

• Basic and diluted EPS for Q1 FY27 were ₹5.72, down from ₹6.69 year-over-year.

• Depreciation and finance costs increased due to new bed additions and expansion-related debt.

Outlook and guidance

• Dombivli Hospital expected to reach EBITDA breakeven in 1.5 to 2 years, with ongoing doctor hiring and ramp-up.

• Insurance empanelment at Dombivli is expected to boost patient inflows in coming quarters.

• Phased development continues with new specialties and consultant expansion to support steady ramp-up.

• Margin guidance for FY27 is around 20-21%, factoring in Dombivli's monthly EBITDA loss of INR 2-3 crore.

• CapEx for new projects and pharmaceutical manufacturing to be funded by internal accruals, cash, and prudent leverage, with debt capped at 3x EBITDA.